Form 10-Q Beam Therapeutics Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Beam Therapeutics Inc (BEAM) PT Lowered to $60 at RBC Capital
November 7, 2022 10:51 AM ESTRBC Capital analyst Luca Issi lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $60.00 (from $76.00) while maintaining a Sector Perform rating.
The analyst comments "BEAM is prioritizing the lead HbF-boosting SCD program over the next-gen Makassar. We caught up... More
Beam Therapeutics Inc (BEAM) PT Lowered to $103 at Stifel
November 7, 2022 9:32 AM ESTStifel analyst Benjamin Burnett lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $103.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "We are reiterating our Buy rating on BEAM following 3Q22 updates. Main pushbacks from bears have been on (potentially... More
